Recent News

• 02.06.2026 - HUTCHMED to Announce 2025 Final Results
• 01.14.2026 - HUTCHMED Highlights Publication of Phase III SACHI Results in The Lancet
• 01.07.2026 - HUTCHMED Announces Positive Topline Results of Phase III Part of ESLIM-02 Trial of Sovleplenib for Warm Antibody Autoimmune Hemolytic Anemia in China
• 01.05.2026 - HUTCHMED Initiates Phase III Stage of the Ongoing Trial of the Combination of Surufatinib and Camrelizumab for Treatment-Naïve Pancreatic Ductal Adenocarcinoma
• 12.30.2025 - HUTCHMED Announces NDA Acceptance in China with Priority Review Status for Savolitinib for the treatment of Gastric Cancer Patients with MET Amplification
• 12.29.2025 - HUTCHMED Announces NDA Acceptance in China with Priority Review Status for Fanregratinib in Second-Line Intrahepatic Cholangiocarcinoma

Recent Filings

• 02.06.2026 - EX-99.1 EX-99.1
• 02.06.2026 - 6-K Report of foreign issuer [Rules 13a-16 and 15d-16]
• 01.14.2026 - 6-K Report of foreign issuer [Rules 13a-16 and 15d-16]
• 01.14.2026 - EX-99.1 EX-99.1
• 01.07.2026 - 6-K Report of foreign issuer [Rules 13a-16 and 15d-16]
• 01.07.2026 - EX-99.1 EX-99.1
• 01.05.2026 - EX-99.1 EX-99.1
• 01.05.2026 - 6-K Report of foreign issuer [Rules 13a-16 and 15d-16]
• 12.31.2025 - EX-99.1 EX-99.1
• 12.31.2025 - 6-K Report of foreign issuer [Rules 13a-16 and 15d-16]